RESUMEN
AIMS: The aims of this study were to characterize the frequency of missing data in the National Surgical Quality Improvement Program (NSQIP) database and to determine how missing data can influence the results of studies dealing with elderly patients with a fracture of the hip. PATIENTS AND METHODS: Patients who underwent surgery for a fracture of the hip between 2005 and 2013 were identified from the NSQIP database and the percentage of missing data was noted for demographics, comorbidities and laboratory values. These variables were tested for association with 'any adverse event' using multivariate regressions based on common ways of handling missing data. RESULTS: A total of 26 066 patients were identified. The rate of missing data was up to 77.9% for many variables. Multivariate regressions comparing three methods of handling missing data found different risk factors for postoperative adverse events. Only seven of 35 identified risk factors (20%) were common to all three analyses. CONCLUSION: Missing data is an important issue in national database studies that researchers must consider when evaluating such investigations. Cite this article: Bone Joint J 2018;100-B:226-32.
Asunto(s)
Exactitud de los Datos , Bases de Datos Factuales , Fracturas de Cadera/cirugía , Mejoramiento de la Calidad , Anciano , Comorbilidad , Demografía , Femenino , Humanos , Tiempo de Internación , Masculino , Tempo Operativo , Procedimientos Ortopédicos , Complicaciones Posoperatorias , Medición de Riesgo , Factores de Riesgo , Estados UnidosRESUMEN
AIMS: To determine the incidence and timing of post-operative fevers following shoulder arthroplasty and the resulting investigations performed. PATIENTS AND METHODS: A retrospective review was conducted of all patients undergoing shoulder arthroplasty over a nine-year period. The charts of all patients with a post-operative fever (≥ 38.6°C) were reviewed and the results of all investigations were analysed. RESULTS: A total of 2167 cases (in 1911 patients) were included of whom 92 (4.2%) had a documented fever. Obese cases had a significantly greater risk for fever (relative risk 1.53; 95% confidence interval 1.02 to 2.32; p = 0.041). Investigations were performed in 43/92 cases (46.7%), with a diagnosis being made in six cases (6.6% of the total, two of whom had their diagnosis made post-discharge). CONCLUSION: Around one in 25 cases develop a fever following shoulder arthroplasty; most have no infective aetiology. These patients may be being over-investigated; investigations should be performed in patients with persistent fever or on those with an identifiable source of infection on clinical examination. Cite this article: Bone Joint J 2017;99-B:1515-19.
Asunto(s)
Artroplastía de Reemplazo de Hombro , Fiebre/etiología , Complicaciones Posoperatorias/etiología , Adulto , Anciano , Anciano de 80 o más Años , Femenino , Fiebre/diagnóstico , Fiebre/epidemiología , Estudios de Seguimiento , Humanos , Incidencia , Masculino , Persona de Mediana Edad , Análisis Multivariante , Complicaciones Posoperatorias/diagnóstico , Complicaciones Posoperatorias/epidemiología , Estudios Retrospectivos , Factores de Riesgo , Factores de TiempoRESUMEN
AIMS: While use of large national clinical databases for orthopaedic trauma research has increased dramatically, there has been little study of the differences in populations contained therein. In this study we aimed to compare populations of patients with femoral shaft fractures across three commonly used national databases, specifically with regard to age and comorbidities. PATIENTS AND METHODS: Patients were identified in the Nationwide Inpatient Sample (NIS), National Surgical Quality Improvement Program (NSQIP) and National Trauma Data Bank (NTDB). RESULTS: The distributions of age and Charleston comorbidity index (CCI) reflected a predominantly older population with more comorbidities in NSQIP (mean age 71.5; sd 15.6), mean CCI 4.9; sd 1.9) than in the NTDB (mean age 45.2; sd 21.4), mean CCI = 2.1; sd 2.0). Bimodal distributions in the NIS population showed a more mixed population (mean age 56.9; sd 24.9), mean CCI 3.2; sd 2.3). Differences in age and CCI were all statistically significant (p < 0.001). CONCLUSION: While these databases have been commonly used for orthopaedic trauma research, differences in the populations they represent are not always readily apparent. Care must be taken to understand fully these differences before performing or evaluating database research, as the outcomes they detail can only be analysed in context. TAKE HOME MESSAGE: Researchers and those evaluating research should be aware that orthopaedic trauma populations contained in commonly studied national databases may differ substantially based on sampling methods and inclusion criteria.
Asunto(s)
Bases de Datos Factuales/normas , Fracturas del Fémur/epidemiología , Adolescente , Adulto , Distribución por Edad , Anciano , Anciano de 80 o más Años , Investigación Biomédica/métodos , Investigación Biomédica/normas , Comorbilidad , Bases de Datos Factuales/estadística & datos numéricos , Fracturas del Fémur/cirugía , Humanos , Persona de Mediana Edad , Estados Unidos/epidemiología , Adulto JovenRESUMEN
The aim of this study was to compare the operating time, length of stay (LOS), adverse events and rate of re-admission for elderly patients with a fracture of the hip treated using either general or spinal anaesthesia. Patients aged ≥ 70 years who underwent surgery for a fracture of the hip between 2010 and 2012 were identified from the American College of Surgeons National Surgical Quality Improvement Program (ACS-NSQIP) database. Of the 9842 patients who met the inclusion criteria, 7253 (73.7%) were treated with general anaesthesia and 2589 (26.3%) with spinal anaesthesia. On propensity-adjusted multivariate analysis, general anaesthesia was associated with slightly increased operating time (+5 minutes, 95% confidence interval (CI) +4 to +6, p < 0.001) and post-operative time in the operating room (+5 minutes, 95% CI +2 to +8, p < 0.001) compared with spinal anaesthesia. General anaesthesia was associated with a shorter LOS (hazard ratio (HR) 1.28, 95% CI 1.22 to 1.34, p < 0.001). Any adverse event (odds ratio (OR) 1.21, 95% CI 1.10 to 1.32, p < 0.001), thromboembolic events (OR 1.90, 95% CI 1.24 to 2.89, p = 0.003), any minor adverse event (OR 1.19, 95% CI 1.09 to 1.32, p < 0.001), and blood transfusion (OR 1.34, 95% CI 1.22 to 1.49, p < 0.001) were associated with general anaesthesia. General anaesthesia was associated with decreased rates of urinary tract infection (OR 0.73, 95% CI 0.62 to 0.87, p < 0.001). There was no clear overall advantage of one type of anaesthesia over the other, and surgeons should be aware of the specific risks and benefits associated with each type.
Asunto(s)
Anestesia General , Anestesia Raquidea , Fracturas de Cadera/cirugía , Anciano , Anciano de 80 o más Años , Estudios de Cohortes , Femenino , Humanos , Tiempo de Internación , Masculino , Análisis Multivariante , Tempo Operativo , Readmisión del Paciente , Complicaciones Posoperatorias/epidemiología , Estudios RetrospectivosRESUMEN
A 1-year, single-center, randomized trial demonstrated that the calcineurin inhibitor or adjuvant immunosuppression, independently, does not affect BK-viruria or viremia and that monitoring and pre-emptive withdrawal of immunosuppression was associated with resolution of BK-viremia and absence of clinical BK-nephropathy without acute rejection or graft loss. A retrospective 5-year review of this trial was conducted. In cases of BK viremia, the antimetabolite was withdrawn and for sustained viremia, the calcineurin inhibitor was minimized. Five-year follow-up was available on 97% of patients. Overall 5-year patient survival was 91% and graft survival was 84%. There were no differences in patient-survival by immunosuppressive regimen or presence of BK-viremia. Immunosuppression and viremia did not influence graft survival. Acute rejection occurred in 12% by 5-years after transplant, was less common with tacrolimus versus cyclosporine (9% vs. 18%; p = 0.082), and was lowest with the tacrolimus-azathioprine regimen (5%, p = 0.127). Tacrolimus was associated with better renal function at 5-years (eGFR 63 FK vs. 52 CsA mL/min, p = 0.001). Minimization of immunosuppression upon detection of BK-viremia was associated with excellent graft survival at 5-years, low rejection rates and excellent renal function. It is a safe, short and long-term strategy that resulted in freedom from clinically evident BK-virus nephropathy.
Asunto(s)
Virus BK/efectos de los fármacos , Terapia de Inmunosupresión/métodos , Inmunosupresores/uso terapéutico , Azatioprina/uso terapéutico , Ciclosporina/uso terapéutico , Supervivencia de Injerto/efectos de los fármacos , Humanos , Enfermedades Renales , Pruebas de Función Renal , Tacrolimus/uso terapéutico , ViremiaRESUMEN
OBJECTIVES: To measure the level of sexual partner concurrency and assess its potential role in explaining disparities in HIV prevalence by race/ethnicity among men who have sex with men (MSM). METHODS: A cross-sectional, community-based survey of MSM in San Francisco was conducted in 2008 using time-location sampling. Four different measures of sexual partner concurrency were assessed and compared across race/ethnicity groups: overlap in time with the most recent sexual partners, knowledge of the most recent sexual partner having other partners, any overlap with up to the last five partners and complete overlap with up to the last five partners. RESULTS: A total of 521 MSM was recruited; 10% self-described their race/ethnicity as black, 62% as white, 25% as Latino and 9% as Asian (not mutually exclusive). Black MSM had fewer sexual partners overall, yet had three times the odds that all their partnerships were concurrent compared with non-black MSM (39% vs 17%, respectively, p = 0.034). None of the other measures of concurrency showed racial/ethnic differences. MSM whose partnerships were completely concurrent had a higher number of sexual episodes and unprotected sexual episodes per partnership compared with those whose partners were not completely concurrent. CONCLUSIONS: Findings support the hypothesis that the sexual networks of black MSM rather than individual behaviours account for their higher prevalence of HIV compared with non-black MSM. There remains the need specifically to validate different concurrency measures in larger samples and directly assess them as risk factors for acquiring HIV infection.
Asunto(s)
Infecciones por VIH/etnología , Homosexualidad Masculina/etnología , Parejas Sexuales , Pueblo Asiatico , Población Negra , Estudios Transversales , Hispánicos o Latinos , Humanos , Masculino , Prevalencia , San Francisco/epidemiología , Sexo Inseguro/etnología , Sexo Inseguro/estadística & datos numéricos , Población BlancaRESUMEN
Three neurodegenerative diseases affecting upper and/or lower motor neurons have been associated with loss of ALS2/Alsin function: juvenile amyotrophic lateral sclerosis, primary lateral sclerosis and infantile-onset ascending hereditary spastic paralysis. The distinct neuronal vulnerability and the role of glia in these diseases remains, however, unclear. We here demonstrate that alsin-depleted spinal motor neurons can be rescued from defective survival and axon growth by co-cultured astrocytes. The astrocytic rescue is mediated by a soluble protective factor rather than by cellular contact. Cortical neurons are intrinsically as vulnerable to alsin depletion as spinal motor neurons but cannot be rescued by co-cultured astrocytes. To our knowledge, these data provide the first example of non-cell-autonomous glial effects in a recessive form of motor neuron disease and a potential rationale for the higher vulnerability of upper versus lower motor neurons in ALS2/Alsin-linked disorders.
Asunto(s)
Astrocitos/metabolismo , Corteza Cerebral/citología , Factores de Intercambio de Guanina Nucleótido/metabolismo , Enfermedad de la Neurona Motora/metabolismo , Neuronas Motoras/metabolismo , Columna Vertebral/citología , Animales , Línea Celular , Células Cultivadas , Corteza Cerebral/metabolismo , Corteza Cerebral/fisiopatología , Modelos Animales de Enfermedad , Factores de Intercambio de Guanina Nucleótido/genética , Humanos , Ratones , Ratones Noqueados , Enfermedad de la Neurona Motora/genética , Enfermedad de la Neurona Motora/fisiopatología , Columna Vertebral/metabolismo , Columna Vertebral/fisiopatologíaRESUMEN
This study sought to evaluate serology and PCR as tools for measuring BK virus (BKV) replication. Levels of immunoglobulin G (IgG), IgM, and IgA against BKV capsids were measured at five time points for 535 serial samples from 107 patients by using a virus-like particle-based enzyme-linked immunosorbent assay. Viral DNA in urine and plasma samples was quantitated. The seroconversion rate was 87.5% (14/16); 78.6% (11/14) and 14.3% (2/14) of patients who seroconverted developed viruria and viremia, respectively. Transient seroreversion was observed in 18.7% of patients at 17.4 +/- 11.9 weeks posttransplant and was not attributable to loss of antigenic stimulation, changes in immunosuppression, or antiviral treatment. Titers for anti-BK IgG, IgA, and IgM were higher in patients with BKV replication than in those without BKV replication. A rise in the optical density (OD) of anti-BK IgA (0.19), IgM (0.04), or IgG (0.38) had a sensitivity of 76.6 to 88.0% and a specificity of 71.7 to 76.1% for detection of viruria. An anti-BK IgG- and IgA-positive phenotype at week 1 was less frequent in patients who subsequently developed viremia (14.3%) than in those who subsequently developed viruria (42.2%) (P = 0.04). Anti-BK IgG OD at week 1 showed a weak negative correlation with peak urine viral load (r = -0.25; P = 0.05). In summary, serial measurements of anti-BKV immunoglobulin class (i) detect onset of viral replication, (ii) document episodes of seroreversion, and (iii) can potentially provide prognostic information.
Asunto(s)
Anticuerpos Antivirales/sangre , Virus BK/aislamiento & purificación , ADN Viral/análisis , Trasplante de Riñón/efectos adversos , Reacción en Cadena de la Polimerasa/métodos , Infecciones por Polyomavirus/diagnóstico , Infecciones Tumorales por Virus/diagnóstico , Adulto , Proteínas de la Cápside/inmunología , ADN Viral/sangre , ADN Viral/orina , Ensayo de Inmunoadsorción Enzimática/métodos , Femenino , Humanos , Inmunoglobulina A/sangre , Inmunoglobulina G/sangre , Inmunoglobulina M/sangre , Estudios Longitudinales , Masculino , Persona de Mediana Edad , Sensibilidad y Especificidad , Viremia , VirosomasRESUMEN
Organic amines are prevalent in nature and in drugs, especially the psychotherapeutic agents, and a major defense against potentially toxic amines is metabolism by CYP2D6. In order to understand better the constraints on the broad specificity of CYP2D6, 4207 amines were docked into the binding site of this enzyme. Docking poses were found predominantly with the positively charged amino groups closest to Asp301, with aromatic rings close to Phe120 and sometimes extending as far as Phe483. Organic amines that bind best to CYP2D6 tend to have larger molecular weights and logP values. Organic amines that score highly as being druglike, based on a Bayesian model constructed using a 5223-drug training set, are least likely to bind to CYP2D6. This correlation suggests that the set of known drugs, which have been largely designed or selected to avoid high affinity CYP binding, partially encodes the binding site preferences (or rather anti-preferences) of CYP2D6. Finally, in order to benchmark our docking and druglike scoring procedures, an analysis of psychotherapeutic agents is presented. All of these data, including the 4207 AM1-optimized ligand structures in proper ionization states, docking poses and scores, Druglike Scores and Lipinski properties, can be viewed from an online database, the AmineDB.
Asunto(s)
Aminas/metabolismo , Citocromo P-450 CYP2D6/metabolismo , Fase I de la Desintoxicación Metabólica/fisiología , Teorema de Bayes , Sitios de Unión/fisiología , Bases de Datos Factuales , Evaluación Preclínica de Medicamentos , Humanos , Ligandos , Psicotrópicos/metabolismo , Especificidad por Sustrato , Xenobióticos/metabolismoRESUMEN
Prophylaxis reduces cytomegalovirus (CMV) disease, but is associated with increased costs and risks for side effects, viral resistance and late onset CMV disease. Preemptive therapy avoids drug costs but requires frequent monitoring and may not prevent complications of asymptomatic CMV replication. Kidney transplant recipients at risk for CMV (D+/R-, D+/R+, D-/R+) were randomized to prophylaxis (valganciclovir 900 mg q.d. for 100 days, n=49) or preemptive therapy (900 mg b.i.d. for 21 days, n=49) for CMV DNAemia (CMV DNA level>2000 copies/mL in >or=1 whole blood specimens by quantitative PCR) assessed weekly for 16 weeks and at 5, 6, 9 and 12 months. More patients in the preemptive group, 29 (59%) than in the prophylaxis group, 14 (29%) developed CMV DNAemia, p=0.004. Late onset of CMV DNAemia (>100 days after transplant) occurred in 11 (24%) randomized to prophylaxis, and none randomized to preemptive therapy. Symptomatic infection occurred in five patients, four (3 D+/R- and 1 D+/R+) in the prophylactic group and one (D+/R-) in the preemptive group. Peak CMV levels were highest in the D+/R- patients. Both strategies were effective in preventing symptomatic CMV. Overall costs were similar and insensitive to wide fluctuations in costs of either monitoring or drug.
Asunto(s)
Antivirales/uso terapéutico , Infecciones por Citomegalovirus/prevención & control , Ganciclovir/análogos & derivados , Enfermedades Renales/prevención & control , Trasplante de Riñón , Complicaciones Posoperatorias/prevención & control , Administración Oral , Adulto , Profilaxis Antibiótica , Antivirales/economía , Análisis Costo-Beneficio , Citomegalovirus/genética , Citomegalovirus/aislamiento & purificación , Infecciones por Citomegalovirus/diagnóstico , Infecciones por Citomegalovirus/virología , ADN Viral/sangre , Ganciclovir/uso terapéutico , Humanos , Enfermedades Renales/virología , Persona de Mediana Edad , Reacción en Cadena de la Polimerasa , Complicaciones Posoperatorias/diagnóstico , Complicaciones Posoperatorias/virología , Valganciclovir , Carga ViralRESUMEN
Mechanisms governing the induction of effective erythropoiesis in response to erythropoietin (Epo) oversecretion have been investigated in beta thalassemic C57Bl/6(Hbbth) mice. Naked DNA encoding an expression vector for mouse Epo was introduced into skeletal muscles by electrotransfer. A transient increase of serum Epo concentrations with a proportional augmentation of hematocrit values was observed. Various parameters relevant to beta thalassemia were surveyed in blood samples taken before treatment, at the peak of Epo secretion, and when the phenotype reverted to anemia. We measured globin messenger RNA (mRNA) levels in reticulocytes by real-time quantitative polymerase chain reaction, globin chain synthesis levels, and several indicators of erythrocyte membrane quality, including bound alpha chains, bound immunoglobulins, main protein components, and iron compartmentalization. Data indicated that high serum Epo levels primarily affect betaminor-globin mRNA accumulation in reticulocytes. Other changes subsequent to intense Epo stimulation, like increased betaminor/alpha-globin chain synthesis ratio, reduced levels of alpha chains and immunoglobulins bound to membranes, improved spectrin/band 3 ratio, increased red blood cell survival, and improved erythropoiesis appeared as consequences of increased betaminor-globin mRNA levels. This conclusion is consistent with models postulating that intense Epo stimulation induces the expansion and differentiation of erythroid progenitors committed to fetal erythropoiesis. Although phenotypic correction was partial in mice, and comparable achievements will probably be more difficult to obtain in humans, naked DNA electrotransfer may provide a safe and low-cost method for reassessing the potentials of Epo as an inducer of fetal erythropoiesis reactivation in patients with beta thalassemia.
Asunto(s)
ADN Complementario/genética , Eritropoyesis/genética , Eritropoyetina/genética , Globinas/genética , Músculo Esquelético/metabolismo , ARN Mensajero/biosíntesis , Reticulocitos/metabolismo , Talasemia beta/genética , Animales , Proteína 1 de Intercambio de Anión de Eritrocito/análisis , Compartimento Celular , Diferenciación Celular , ADN Complementario/administración & dosificación , Modelos Animales de Enfermedad , Electroporación , Eritrocitos/metabolismo , Células Precursoras Eritroides/metabolismo , Células Precursoras Eritroides/patología , Eritropoyetina/sangre , Prueba de Complementación Genética , Inyecciones Intramusculares , Hierro/metabolismo , Ratones , Ratones Endogámicos C57BL , Ratones Noqueados , Fenotipo , Reacción en Cadena de la Polimerasa , Proteínas Recombinantes de Fusión/biosíntesis , Proteínas Recombinantes de Fusión/fisiología , Espectrina/análisis , TransfecciónRESUMEN
Erythropoietin (Epo) is a glycoprotein hormone produced by genetic engineering. Many pathologic conditions could benefit from its administration, such as chronic renal failure or hemoglobinopathies. Epo secretion from genetically modified tissued could be proposed to patients only if the protocol is low cost and low risk. For that purpose, retroviral vectors and adeno-associated vectors expressing the Epo cDNA were developed. Gene transfer was performed into skeletal muscles. To avoid polycythemia, a tetracycline-regulated system was used to control the levels of protein secretion in vivo. beta-thalassemias are among diseases that could benefit from an Epo gene transfer. beta-thalassemias are attributable to deficient synthesis of beta-globin and accumulation of unpaired alpha-chains. Stimulation of fetal globin synthesis is one strategy to correct the globin chain imbalance. There is evidence that Epo could play this role. In a mouse model of beta-thalassemia, an adeno-associated vector expressing the Epo cDNA was injected intramuscularly. Epo was secreted continuously during at least 1 yr. Erythropoiesis was improved in those mice by increasing the synthesis of fetal hemoglobin.
Asunto(s)
Trasplante de Células , Eritropoyetina/administración & dosificación , Ingeniería Genética , Animales , Eritropoyetina/genética , Eritropoyetina/uso terapéutico , Técnicas de Transferencia de Gen , Terapia Genética , Humanos , Talasemia beta/terapiaRESUMEN
beta-Thalassemias are highly prevalent genetic disorders that can cause severe hemolytic anemia. The main pathophysiologic feature of beta-thalassemia is the accumulation of unpaired alpha-globin chains in erythrocyte precursors and red blood cells (RBCs). This accumulation alters cell membrane function and results in early cell destruction and ineffective erythropoiesis. Correction of globin chain imbalance through the induction of fetal hemoglobin (HbF) synthesis is a tentative therapeutic approach for this class of diseases. In short-term in vitro or in vivo assays, recombinant human erythropoietin increases the frequency of erythroid precursors programmed to HbF in humans and to beta-minor globin in mice. In contrast, long-term treatment of beta-thalassemic patients did not induce HbF significantly. We took advantage of highly efficient adeno-associated virus-mediated (AAV-mediated) gene transfer into mouse muscle to induce a robust and sustained secretion of mouse erythropoietin in beta-thalassemic mice, which represent a suitable model for human beta-thalassemia intermedia. A 1-year follow-up of 12 treated animals showed a stable correction of anemia associated with improved RBC morphology, increased beta-minor globin synthesis, and decreased amounts of alpha-globin chains bound to erythrocyte membranes. More effective erythropoiesis probably accounted for a reduction of erythroid cell proliferation, as shown by decreased proportions of circulating reticulocytes and by reduced iron 59 ((59)Fe) incorporation into erythroid tissues. This study indicates that the continuous delivery of high amounts of autologous erythropoietin induced a sustained stimulation of beta-minor globin synthesis and a stable improvement of erythropoiesis in the beta-thalassemic mouse model. (Blood. 2000;95:2793-2798)
Asunto(s)
Eritropoyesis , Eritropoyetina/genética , Terapia Genética , Talasemia beta/terapia , Animales , División Celular , Dependovirus , Recuento de Eritrocitos , Eritropoyetina/fisiología , Técnicas de Transferencia de Gen , Vectores Genéticos , Globinas/biosíntesis , Hematócrito , Humanos , Hierro/metabolismo , Ratones , Ratones Mutantes , Músculo Esquelético , Recuento de Reticulocitos , Talasemia beta/sangreRESUMEN
Cell encapsulation offers a safe and manufacturable method for the systemic delivery of therapeutic proteins from genetically engineered cells. However, control of dose delivery remains a major issue with regard to clinical application. We generated populations of immortalized murine NIH 3T3 fibroblasts that secrete mouse erythropoietin (Epo) in response to stimulation by doxycycline or mifepristone. Engineered cells were introduced into AN69 hollow fibers, which were implanted in the peritoneal cavity or recipient mice. Animals receiving doxycycline or mifepristone showed stable polyhemia and increased serum Epo concentrations over a 6-month observation period, whereas animals not receiving the inducer drug had normal hematocrits. Epo secretion could be switched on and off, depending on the presence of doxycycline in the drinking water. In contrast, polyhemia was hardly reversible after subcutaneous injections of mifepristone. These data show that a permanent and regulated systemic delivery of a therapeutic protein can be obtained by the in vivo implantation of engineered allogeneic cells immunoprotected in membrane polymers.
Asunto(s)
Doxiciclina/farmacología , Eritropoyetina/metabolismo , Mifepristona/farmacología , Células 3T3 , Animales , Southern Blotting , Cápsulas , Relación Dosis-Respuesta a Droga , Doxiciclina/administración & dosificación , Eritropoyetina/sangre , Regulación de la Expresión Génica , Técnicas de Transferencia de Gen , Terapia Genética/métodos , Hematócrito , Ratones , Mifepristona/administración & dosificación , Retroviridae , Factores de TiempoRESUMEN
The skeletal muscle provides a very permissive physiological environment for adeno-associated virus (AAV) type 2-mediated gene transfer. We have studied the early steps leading to the establishment of permanent transgene expression, after injection of recombinant AAV (rAAV) particles in the quadriceps muscle of mice. The animals received an rAAV encoding a secreted protein, murine erythropoietin (mEpo), under the control of the human cytomegalovirus major immediate-early promoter and were sacrificed between 1 and 60 days after injection. The measurement of plasma Epo levels and of hematocrits indicated a progressive increase of transgene expression over the first 2 weeks, followed by a stabilization at maximal plateau values. The rAAV sequences were analyzed by Southern blotting following neutral or alkaline gel electrophoresis of total DNA from injected muscles. While a high number of rAAV sequences were detected during the first 5 days following the injection, only a few percent of these sequences was retained in the animals analyzed after 2 weeks, in which transgene expression was maximal. Double-stranded DNA molecules resulting from de novo second-strand synthesis were detected as early as day 1, indicating that this crucial step of AAV-mediated gene transfer is readily accomplished in the muscle. The templates driving stable gene expression at later time points are low in copy number and structured as high-molecular-weight concatemers or interlocked circles. The presence of the circular form of the rAAV genomes at early time points suggests that the molecular transformations involved in the formation of stable concatemers may involve a rolling-circle type of DNA replication.
Asunto(s)
ADN Viral/química , Dependovirus/genética , Técnicas de Transferencia de Gen , Vectores Genéticos , Músculo Esquelético/metabolismo , Animales , Replicación del ADN , Ratones , Ratones Endogámicos BALB CRESUMEN
BACKGROUND: Recombinant adeno-associated viral (rAAV) vectors are capable of long-term expression of secreted and intracellular proteins following delivery to muscle, liver, and the central nervous system. In this study, we have evaluated subcutaneous injection of rAAV encoding a variety of transgenes as an alternative route of administration for the systemic delivery of therapeutic proteins. METHODS: rAAV vectors encoding the human factor IX, human interferon-alpha 2a, murine erythropoietin (epo), and Escherichia coli lacZ genes were used for subcutaneous delivery into mature immunocompetent mice. Expression of factor IX and interferon in mouse serum was measured by ELISA. Expression of Epo was monitored by an increase in hemotocrit and by RIA. The tissue tropism of AAV transduction was determined by histochemistry following administration of the lacZ vector. RESULTS: Long-term protein expression (at least one year) is demonstrated in the serum of immunocompetent mice following subcutaneous delivery of AAV vectors encoding the human factor IX and interferon genes. The murine epo gene delivered via this route resulted in levels of Epo that correlate with increased hematocrits of up to 90% for a duration of nine months. rAAV encoding the lacZ gene revealed that the panniculus carnosus, a skeletal muscle layer of the skin, was transduced upon subcutaneous administration. CONCLUSIONS: This study shows that long-term expression of secreted proteins can be achieved using rAAV vectors injected subcutaneously as a single administration. The observation that the panniculus carnosus is the primary tissue transduced by rAAV illustrates the high tropism of rAAV for skeletal muscle.
Asunto(s)
Dependovirus/genética , Vectores Genéticos , Animales , Eritropoyetina/sangre , Eritropoyetina/genética , Factor IX/biosíntesis , Factor IX/genética , Femenino , Expresión Génica , Terapia Genética , Humanos , Inyecciones Subcutáneas , Interferón alfa-2 , Interferón-alfa/sangre , Interferón-alfa/genética , Operón Lac , Ratones , Ratones Endogámicos BALB C , Músculo Esquelético/metabolismo , Proteínas Recombinantes , Factores de Tiempo , Distribución Tisular , Transducción GenéticaRESUMEN
We reported previously that controlled expression of a foreign gene in response to tetracycline derivative can be accomplished in mice by the autologous transplantation of retrovirus-modified muscle cells. Although regulated systemic delivery of therapeutic proteins from engineered tissues has potential clinical application, the transplantation of muscle cells is not currently feasible in humans. Several studies have shown that a single injection of adeno-associated virus (AAV) vectors into mouse muscle results in long-term expression of reporter genes as well as sustained delivery of proteins into the serum. Because this method is potentially applicable clinically, we constructed an AAV vector in which the expression of the mouse erythropoietin (Epo) cDNA is modulated in response to doxycycline. The vector was injected intramuscularly in normal mice. We observed that hematocrit and serum Epo concentrations could be modulated over a 29-week period in response to the presence or absence of doxycycline in the drinking water of these animals. Thus, a regulated gene expression cassette can be incorporated into a single AAV vector, such that intramuscular injection of the vector allows sustained and regulated expression of a desired gene.
Asunto(s)
ADN Complementario/administración & dosificación , Dependovirus/genética , Doxiciclina/farmacología , Eritropoyetina/genética , Regulación de la Expresión Génica/efectos de los fármacos , Vectores Genéticos , Animales , Northern Blotting , Células Cultivadas , Doxiciclina/administración & dosificación , Eritropoyetina/metabolismo , Técnicas de Transferencia de Gen , Humanos , Inyecciones Intramusculares , Ratones , Músculos/metabolismo , ARN Mensajero/análisisRESUMEN
Control of gene expression is important to gene therapy for purposes of both dosing and safety. In vivo regulation of gene expression was demonstrated following co-injection of two separate recombinant adeno-associated virus vectors, one encoding an inducible murine erythropoietin transgene and the other a transcriptional activator, directly into the skeletal muscle of adult immunocompetent mice. Transcription was controlled by systemic administration or withdrawal of tetracycline over an 18 week period, demonstrating that the two vectors were capable of transducing the same cell. Cellular or humoral immune responses against the transactivator protein were not detected.
Asunto(s)
Dependovirus/genética , Regulación de la Expresión Génica , Terapia Genética/métodos , Vectores Genéticos/genética , Células 3T3 , Animales , Formación de Anticuerpos , Células Cultivadas , Eritropoyetina/biosíntesis , Eritropoyetina/genética , Femenino , Técnicas de Transferencia de Gen , Vectores Genéticos/administración & dosificación , Hematócrito , Inyecciones Intramusculares , Ratones , Ratones Endogámicos BALB C , Músculo Esquelético/metabolismo , Regiones Promotoras Genéticas , Linfocitos T Citotóxicos/inmunología , Tetraciclina/farmacología , Transactivadores/genética , TransgenesRESUMEN
Many diseases that are candidates for gene therapy require that the therapeutic gene expression level be controlled to ensure biological efficacy and to prevent toxic effects. Various systems have been described that allow transcriptional regulation by artificial chimeric transactivators in mammalian cells. This paper describes these various systems and discusses their interests for gene therapy.
Asunto(s)
Regulación de la Expresión Génica/genética , Terapia Genética/tendencias , Transcripción Genética/genética , Animales , Regulación de la Expresión Génica/efectos de los fármacos , Ingeniería Genética , Humanos , Polienos , Receptores de Esteroides , Proteínas Represoras , Sirolimus , Tetraciclina , Resistencia a la Tetraciclina/genética , Transcripción Genética/efectos de los fármacosRESUMEN
The locus control region (LCR) regulates transcription of the downstream beta-like globin genes 10 to 50 kb away. Among hypersensitive sites HS4, -3, -2, and -1, which define the LCR in erythroid cells, HS2 possesses prominent enhancer function. The mechanism by which the HS2 enhancer and other functional components of the LCR act over the distance is not clear. We have used reverse transcription-PCR and RNase protection assays to analyze the transcriptional statuses of both the endogenous and the transfected HS2 enhancer in erythroid K562 cells. A novel pattern of HS2 enhancer transcription was observed. The endogenous HS2 enhancer was transcribed predominantly in the direction toward the downstream globin genes. The HS2 enhancer in transfected recombinant chloramphenicol acetyltransferase (CAT) plasmids was also transcribed predominantly toward the CAT gene, regardless of whether the enhancer was placed (i) in the genomic or reverse genomic orientation, (ii) in a position 5' or 3' to the gene, or (iii) at various distances up to 6 kb from the gene. The orientation, position, and distance independence in gene-tropic transcription of the HS2 enhancer correlates with the observed orientation, position, and distance independence of HS2 enhancer function and suggests that enhancer transcription may play a role in enhancer function.